Cadrenal Therapeutics, Inc.披露了2026年第一季度的财务业绩，同时就核心药物CAD-1005的三期临床试验规划提供了最新动态。此次进展基于公司与美国食品药品监督管理局（FDA）成功举行的二期临床试验结束会议后所制定的后续开发路径。
Cadrenal Therapeutics, Inc.披露了2026年第一季度的财务业绩，同时就核心药物CAD-1005的三期临床试验规划提供了最新动态。此次进展基于公司与美国食品药品监督管理局（FDA）成功举行的二期临床试验结束会议后所制定的后续开发路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.